elliptinium has been researched along with Bone Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Couette, JE; Delozier, T; Juret, P; Le Talaer, Y | 1 |
| Couette, JE; Delozier, T; Juret, P; Le Talaer, JY | 1 |
| Couette, JE; Delozier, T; Heron, JF; Juret, P; Le Talaer, JY | 1 |
| Blanc, AP; Garrigues, B; Pedinielli, FJ; Routy, JP | 1 |
2 trial(s) available for elliptinium and Bone Cancer
| Article | Year |
|---|---|
Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
Topics: Alkaloids; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Clinical Trials as Topic; Ellipticines; Female; Humans; Middle Aged | 1980 |
[Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
Topics: Adult; Alkaloids; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ellipticines; Female; Follow-Up Studies; Humans; Male | 1981 |
2 other study(ies) available for elliptinium and Bone Cancer
| Article | Year |
|---|---|
Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
Topics: Alkaloids; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Digestive System; Drug Evaluation; Ellipticines; Female; Humans; Kidney; Xerostomia | 1982 |
[Fatal complication during treatment with elliptinium acetate].
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents; Bone Neoplasms; Ellipticines; Female; Hematologic Diseases; Humans; Middle Aged | 1985 |